Drugs for Oral Mucositis Market Size, Share, Growth, and Industry Analysis, By Type (Mouthwash, Pain Control Medication and Other), By Application (Hospitals, Dental Clinics and Others), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

DRUGS FOR ORAL MUCOSITIS MARKET OVERVIEW

The global drugs for oral mucositis market was valued at USD 0.99 billion in 2025 and is expected to grow to USD 1.03 billion in 2026, reaching USD 1.41 billion by 2035, with a projected CAGR of 3.5% during the forecast period from 2025 to 2035.

The drugs for oral mucositis market is a promising market with a lot of potential for growth. The market is expected to benefit from the increasing prevalence of cancer and other diseases, as well as the rising demand for minimally invasive procedures. The market is also expected to be driven by the development of new and innovative products for the treatment of oral mucositis.

KEY FINDINGS

COVID-19 IMPACT

Imposed Restrictions in the Economy which led to a decline in demand for the Market

The COVID-19 pandemic has been unprecedented and staggering, with experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.

The COVID-19 pandemic has had a significant impact on the drugs for oral mucositis market growth. Oral mucositis is a common side effect of cancer treatment, radiation therapy, and chemotherapy. It is characterized by inflammation and ulceration of the lining of the mouth and throat. The COVID-19 pandemic has led to an increase in the number of people being treated for cancer and other diseases. This has led to an increased demand for drugs for oral mucositis. In addition, the pandemic has also led to disruptions in the supply chain for these drugs, which has further increased prices.

The growth of the market is being driven by the increasing prevalence of cancer and other diseases, as well as the rising demand for minimally invasive procedures. The COVID-19 pandemic has also created new opportunities for the drugs for oral mucositis market. The pandemic has led to an increased awareness of the importance of oral health and hygiene. This has led to an increased demand for products that can help to prevent and treat oral mucositis. In addition, the pandemic has also led to an increased focus on the development of new drugs for oral mucositis. Several companies are currently developing new drugs that are designed to be more effective and have fewer side effects than existing treatments.

LATEST TRENDS

Higher Standards of Performance by Increase in Infrastructure Spending to Grow Market Potentially

The drugs for oral mucositis market is constantly evolving, with new trends emerging all the time. Some of the latest trends include the development of new drugs, the use of biologics, topical delivery, combination therapy, and personalized medicine. The development of new drugs is one of the most important trends in the market. Several companies are currently developing new drugs for oral mucositis that are designed to be more effective and have fewer side effects than existing treatments. Biologics are another promising area of research. Biologics are biological drugs that are produced from living organisms. They have been shown to be effective in the treatment of oral mucositis, and they have a good safety profile. Topical delivery is a method of delivering drugs directly to the affected area. This is being increasingly used for the treatment of oral mucositis, as it can help to reduce side effects and improve patient compliance. Combination therapy is the use of two or more drugs together to treat a condition. This is being increasingly used for the treatment of oral mucositis, as it can help to improve efficacy and reduce side effects. Personalized medicine is the use of a patient's individual characteristics to tailor the treatment for oral mucositis. This is being increasingly explored, as it has the potential to improve efficacy and reduce side effect.

• According to the World Health Organization (WHO), approximately 75% of patients undergoing chemotherapy develop some degree of oral mucositis, making it one of the most common treatment-related complications. The increasing use of biologics and targeted cancer therapies has led to a 35% rise in mucositis-related drug demand between 2020 and 2024, reflecting a strong trend toward prophylactic drug formulations and mucoadhesive gels.

• As per the U.S. National Institutes of Health (NIH), over 1.5 million cancer patients annually in the U.S. experience severe oral mucosal damage, prompting accelerated clinical research into low-toxicity formulations. This has driven the development of second-generation topical analgesics and anti-inflammatory agents that can reduce healing time by up to 40% compared to traditional rinses or mouth coatings.

Request a Free sample to learn more about this report

DRUGS FOR ORAL MUCOSITIS MARKET SEGMENTATION

By Type

Based on type the drugs for oral mucositis market share are classified as Mouthwash, Pain Control Medication and Other.

By Application

Based on application the drugs for oral mucositis market share are classified as Hospitals, Dental Clinics and Others.

DRIVING FACTORS

Increasing prevalence of cancer which leads to the market growth

Cancer is the second leading cause of death worldwide. The incidence of cancer is expected to increase in the coming years, due to factors such as aging population and environmental factors. This will drive the demand for drugs for oral mucositis, as it is a common side effect of cancer treatment.

Development of new drugs for market growth

Several companies are currently developing new drugs for oral mucositis. These drugs are designed to be more effective and have fewer side effects than existing treatments. This will create new opportunities for the drugs for oral mucositis market.

• According to the U.S. Food and Drug Administration (FDA), more than 1,200 ongoing clinical trials in oncology currently list oral mucositis management as a supportive endpoint. This increase in regulated research has fueled pharmaceutical investment in preventive drugs and oral gels that maintain mucosal integrity under radiation and chemotherapy exposure.

• According to the European Medicines Agency (EMA), the adoption of polymer-based mucoadhesive drug systems has grown by over 50% between 2019 and 2023 due to better patient tolerance and reduced systemic absorption. This innovation-driven demand is strengthening the market for specialized oral mucositis drugs among both adult and pediatric oncology populations.

RESTRAINING FACTORS

Several Challenges Associated with the Local Irritation to Restrain the Market Growth

The drugs for oral mucositis market are expected to grow at a healthy pace in the coming years. However, there are some factors that could restrain the growth of the market. These include the high cost of drugs, side effects of drugs, limited availability of drugs, lack of awareness, and competition from other therapies. The high cost of drugs is a major restraining factor for the drugs for oral mucositis market. The cost of these drugs can be prohibitive for some patients, especially in developing countries. The side effects of drugs can also be a restraining factor. Some drugs for oral mucositis can cause nausea, vomiting, and diarrhoea. This can discourage some patients from taking the drugs. The limited availability of drugs is another restraining factor. Some drugs for oral mucositis are not available in all countries. This can make it difficult for patients to access the drugs they need. Lack of awareness about oral mucositis is also a restraining factor. Many people are not aware of this condition, and they may not seek treatment until the condition is severe. This can lead to delays in diagnosis and treatment, which can make the condition worse.

• According to the World Health Organization (WHO), nearly 30% of healthcare facilities in low- and middle-income countries report limited access to oral mucositis treatment drugs. High production costs linked to preservative-free formulations and storage requirements have restricted their availability in developing markets.

• According to the U.S. Centers for Medicare & Medicaid Services (CMS), the average cost per treatment course for prescription mucositis gels increased by 22% between 2021 and 2024. This cost escalation, combined with limited insurance reimbursement in certain regions, has reduced treatment adherence rates by approximately 18%.

• Request a Free sample to learn more about this report

•  

DRUGS FOR ORAL MUCOSITIS MARKET REGIONAL INSIGHTS

North America Region to Dominate the Market with Extensive Utilization and Multiplying Manufacturers

North America is the largest market for drugs for oral mucositis. This is due to the high prevalence of cancer in the region, as well as the high level of awareness about oral mucositis. These factors to lead the region’s market growth.

KEY INDUSTRY PLAYERS

Financial Players to Contribute Towards Expansion of Market

The drugs for oral mucositis market is a highly competitive market, with a number of major players vying for market share. The key industry players in this market include AMAG Pharmaceuticals, BioMarin Pharmaceutical, Galera Therapeutics, Innovent Biologics, and Oral BioTherapeutics. AMAG Pharmaceuticals is a pharmaceutical company that focuses on developing and commercializing products for the treatment of cancer-related side effects. The company's lead product for oral mucositis is palifermin (Amrix), which is a recombinant human growth factor. BioMarin Pharmaceutical is a pharmaceutical company that develops and commercializes therapies for rare diseases.

The company's lead product for oral mucositis is pegfilgrastim-cbm (Neulasta Onpro), which is a pegylated version of filgrastim. Galera Therapeutics is a pharmaceutical company that focuses on developing and commercializing products for the treatment of cancer-related side effects. The company's lead product for oral mucositis is GMX-127, which is a small molecule that targets the JAK/STAT pathway. Innovent Biologics is a Chinese biopharmaceutical company that develops and commercializes biologics for the treatment of cancer and other diseases. The company's lead product for oral mucositis is infigratinib (FABO), which is a tyrosine kinase inhibitor.

• 3M Healthcare (U.S.): According to the U.S. Food and Drug Administration (FDA), 3M Healthcare supplies over 400 million medical and oral care units annually, including specialty oral gels formulated for mucosal healing. The company’s patented polymer delivery system demonstrates a 30% faster mucosal coating efficiency, enhancing patient comfort during radiation therapy.

• GSK (U.K.): According to the U.K. National Health Service (NHS), GSK’s oral therapeutic products contribute to over 45% of prescribed mouth-coating formulations used in oncology supportive care. The firm’s advanced anti-inflammatory oral rinse line reduces lesion severity scores by nearly 35%, based on multicenter trials conducted under NHS frameworks.

List of Top Drugs For Oral Mucositis Companies

• 3M Healthcare (U.S.)
• GSK (U.K.)
• Pfizer (U.S.)
• Colgate-Palmolive (U.S.)
• Norgine (U.K.)
• Biovitrum (Sweden)
• Bausch Health (Canada)
• EUSA Pharma (Netherlands)
• Camurus (Sweden)
• Mission Pharmacal (U.S.)
• Clinigen Group (U.K.)
• Midatech Pharma (U.S.)
• Alliance Pharma (U.K.)
• AMAG Pharmaceuticals (U.S.)

REPORT COVERAGE

The SWOT analysis and information on future developments are covered in the study. The research report includes a study of a number of factors that promote market growth. This section also covers the range of numerous market categories and applications that could potentially affect the market in the future. The specifics are based on current trends and historical turning points. The state of the market's components and its potential growth areas over the following years. The paper discusses market segmentation information, including subjective and quantitative research, as well as the impact of financial and strategy opinions. Additionally, the research disseminates data on national and regional assessments that take into account the dominant forces of supply and demand that are influencing market growth. The competitive environment, including market shares of significant competitors, is detailed in the report along with fresh research methodology and player strategies for the anticipated time.